Therapeutic Strategies to Overcome ALK Resistance in Cancer presents current strategies to improve and prolong clinical benefit in ALK driven cancers. Most patients with ALK-driven cancer are sensitive to tyrosine kinase inhibitor (TKI) therapy, but resistance invariably develops. Therefore, effective therapeutic strategies for patients who have become resistant to currently available TKIs have been investigated and can prolong patient benefit to targeted treatment. The book discusses topics such as structure and function of ALK, ALK rearranged lung cancer, resistance mechanisms to ALK TKI tumors, and novel therapeutic startegies to enhance crizotinib anti-tumor efficacy in ALCL. Additionally, it encompasses information on drug combinations to enhance ALK TKI anti-tumor efficacy in neuroblastoma and future perspectives in the field. This book is a valuable resource for cancer researchers, clinicians and several members of biomedical field who need to understand more about how to fight ALK resistance in cancer treatment. Explains the biology of ALK RTK, focusing on its tissue expression, structure and functionality Presents an overview of current treatment and benefit of ALK TKI in lung and other cancer types such as ALCL, neuroblastoma, and inflammatory myofibroblastic tumor Encompasses information on systemic treatments other than TKI: chemotherapy, immunotherapy and antiangiogenic agents in ALK-driven NSCLC INDICE: 1. Structure and function of ALK2. ALK rearranged lung cancer: Treatment and outcome3. Systemic treatments other than TKI: reflections on chemotherapy, immunotherapy and antiangiogenic agents in ALK-driven NSCLC4. Management of ALK positive patients with tumors other than lung cancer (ALCL, neuroblastoma, Inflammatory Myofibroblastic Tumor)5. Resistance mechanisms to ALK TKIs in lung cancer: from single to compound mutations, from tissue to liquid biopsy6. Resistance mechanisms to ALK TKI in tumors other than lung cancer7. Therapeutic strategies to overcome ALK resistance in lung cancer8. Novel Therapeutic strategies to enhance crizotinib anti-tumor efficacy in ALCL: use of ACD9. Drug combinations to enhance ALK TKI anti-tumor efficacy in Neuroblastoma10. State of the art and future perspectives
- ISBN: 978-0-12-821774-0
- Editorial: Academic Press
- Encuadernacion: Cartoné
- Páginas: 200
- Fecha Publicación: 01/10/2020
- Nº Volúmenes: 1
- Idioma: Inglés